SETD2 in Tumor Metabolism and Immunotherapy: A Meta-Analysis of 78 Studies

78 studies encompassing approximately 12,400 patients across 12 cancer types were synthesized in this systematic review and meta-analysis. The work by Chunhui Liu, last updated in March 2026, analyzes the role of the SETD2 gene in metabolic reprogramming and response to immunotherapy. It reports pooled odds and hazard ratios linking SETD2 loss to altered tumor metabolism and reduced clinical benefit from immune checkpoint inhibitors.

Use Cases

• Validate findings on SETD2's association with metabolic reprogramming based on the reported pooled odds ratio of 2.34.
• Investigate the correlation between SETD2 deficiency and immunotherapy resistance based on the reported hazard ratio of 1.56.
• Explore mechanistic links between epigenetic regulation and immune cell infiltration based on described reductions in CD8+ T cells.
• Design combination therapy strategies for SETD2-deficient tumors based on the conclusion's suggested metabolic–immunotherapy approaches.

Strengths

• Analysis synthesizes data from 78 studies and approximately 12,400 patients.
• Follows PRISMA 2020 guidelines for systematic review methodology.
• Includes subgroup and sensitivity analyses to explore substantial statistical heterogeneity (I² = 52–68%).

Limitations

• The dataset is a 467.5 KB DOC file, suggesting limited raw data scope; it is primarily a manuscript.
• Column-level documentation is absent; field semantics must be inferred after download.
• The exploratory protocol was not registered, which may affect reproducibility.

Provenance

Source

Chunhui Liu via figshare.

Collection Method

Systematic review and meta-analysis of studies from PubMed, EMBASE, Web of Science, and Cochrane databases.

Time Range

Literature search from database inception through April 2024.

Freshness

Last updated 2026-03-18 07:45:05

Geography

null